GlassScriptPhysician profile
Amanda Stolarz
NPI 1124774724
$1,760.43
in general payments reported to CMS, 2019-2025
18 companies · $537 in 2025
The $537 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.05 · 2023: $470 · 2024: $737 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.55 | 2023-2025 | |
| Novo Nordisk INC | $282.06 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $234.02 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $167.82 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.63 | 2025 | Caplyta |
| Lilly USA, LLC | $106.39 | 2022-2025 | Mounjaro, Zepbound |
| Almatica Pharma LLC | $106.11 | 2024-2025 | Loreev Xr |
| Astrazeneca Pharmaceuticals LP | $75.51 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $61.66 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $58.02 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $40.47 | 2023 | |
| Corcept Therapeutics | $39.23 | 2023 | Korlym |
| Edwards Lifesciences Corporation | $33.74 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $21.79 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.53 | 2024 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $15.11 | 2024 | Xyosted |
| Glaxosmithkline, LLC. | $14.29 | 2023 | Shingrix |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Stolarz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.